New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
09:34 EDTNWBONorthwest Biotherapeutics refutes claims by Adam Feuerstein
Northwest Biotherapeutics refuted the statements made by Adam Feuerstein in an article on Tuesday, May 27. Regarding Feuerstein's headline, "Cancer Patients Aren't Responding to Northwest Bio's DCVax-Direct" and the claim that "None of the 19 patients with advanced, metastatic cancers have responded to treatment with DCVax-Direct in an ongoing Phase I clinical trial", Northwest stated that "While still only part way through treatment, more than 50% of these patients - 11 of the 19 - have already shown tumor shrinkage of up to 28%, substantial tumor cell death and substantial accumulation of immune cells in the tumors." Regarding Feuerstein's claim that "Under the globally accepted definition of tumor response known as RECIST, a partial response requires a 30% reduction in the size of the target lesion. DCVax-Direct: 0% response rate", Northwest stated that "There are numerous types of established measures of patient responses to treatments. The measures reported in the company's announcement are considered clinically significant and are regularly the focus of peer reviewed scientific and medical publications in oncology, particularly for late stage disease. Further, the RECIST criteria themselves include multiple categories."
News For NWBO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for NWBO

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use